WO2009153175A1 - Procédés et moyens de diagnostic du cancer du pancréas - Google Patents

Procédés et moyens de diagnostic du cancer du pancréas Download PDF

Info

Publication number
WO2009153175A1
WO2009153175A1 PCT/EP2009/056951 EP2009056951W WO2009153175A1 WO 2009153175 A1 WO2009153175 A1 WO 2009153175A1 EP 2009056951 W EP2009056951 W EP 2009056951W WO 2009153175 A1 WO2009153175 A1 WO 2009153175A1
Authority
WO
WIPO (PCT)
Prior art keywords
amount
subject
pancreatic cancer
sic3b
sample
Prior art date
Application number
PCT/EP2009/056951
Other languages
English (en)
Inventor
Angela MÄRTEN
Original Assignee
Universitätsklinikum Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitätsklinikum Heidelberg filed Critical Universitätsklinikum Heidelberg
Publication of WO2009153175A1 publication Critical patent/WO2009153175A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne le domaine du diagnostic de cancer. En particulier, la présente invention concerne un procédé permettant le diagnostic du cancer du pancréas chez un sujet comprenant les étapes de détermination de la quantité de siC3b dans un échantillon d’un sujet et la comparaison de ladite quantité à une quantité de référence, permettant ainsi le diagnostic du cancer du pancréas. La présente invention concerne également un procédé permettant de déterminer si un sujet doit être suivi de près pour un cancer du pancréas et un procédé permettant de déterminer si une thérapie anticancéreuse appliquée au sujet après le traitement du cancer du pancréas est bénéfique. L’invention concerne en outre des dispositifs et des trousses de diagnostic pour la mise en œuvre desdits procédés.
PCT/EP2009/056951 2008-06-16 2009-06-05 Procédés et moyens de diagnostic du cancer du pancréas WO2009153175A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08158346 2008-06-16
EP08158346.0 2008-06-16

Publications (1)

Publication Number Publication Date
WO2009153175A1 true WO2009153175A1 (fr) 2009-12-23

Family

ID=40886127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/056951 WO2009153175A1 (fr) 2008-06-16 2009-06-05 Procédés et moyens de diagnostic du cancer du pancréas

Country Status (1)

Country Link
WO (1) WO2009153175A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030426A1 (fr) * 2014-08-26 2016-03-03 Roland Andersson Procédé de détermination probabiliste de prédisposition d'un patient au cancer du pancréas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102526A1 (fr) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Procédés de diagnostic du cancer du pancréas utilisant la protéine reg4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102526A1 (fr) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Procédés de diagnostic du cancer du pancréas utilisant la protéine reg4

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAN SCHMIDT ET AL: "Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 55, no. 1, 27 October 2005 (2005-10-27), pages 31 - 38, XP019422473, ISSN: 1432-0851 *
LIN YIING ET AL: "Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients.", JOURNAL OF PROTEOME RESEARCH SEP 2006, vol. 5, no. 9, September 2006 (2006-09-01), pages 2169 - 2176, XP002538845, ISSN: 1535-3893 *
QUIDEL CORPORATION: "Quidel iC3b EIA Kit", November 2007 (2007-11-01), XP002538844, Retrieved from the Internet <URL:http://www.quidel.com/libraries/pkginserts/AI/A006_iC3b.pdf> [retrieved on 20090727] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030426A1 (fr) * 2014-08-26 2016-03-03 Roland Andersson Procédé de détermination probabiliste de prédisposition d'un patient au cancer du pancréas
CN107003371A (zh) * 2014-08-26 2017-08-01 瑞可安诊断公司 用于确定主体患胰腺癌的可能性的方法

Similar Documents

Publication Publication Date Title
US11726090B2 (en) Means and methods for diagnosing pancreatic cancer
US8216789B2 (en) Diagnostic panel of cancer antibodies and methods for use
JP2012515335A (ja) 線維症と肝硬変を識別する手段及び方法
JP5606438B2 (ja) 抗血管新生療法を受容可能な被験体の同定
TWI408370B (zh) 胰臟癌之血清生物檢測標誌及其應用
EP3071972B1 (fr) Procédé de diagnostic in vitro et de pronostic de récidive du cancer du sein triple négatif
EP3080299B1 (fr) Biomarqueurs de progression rapide du cancer du poumon non à petites cellules à un stade avancé
EP3839513A1 (fr) Utilisation de complexes de facteur de transcription-adn pour la détection du cancer
AU2017260806A1 (en) Markers of endometrial cancer
JP4515099B2 (ja) Ｌａｓｐ−１免疫反応性の決定によって炎症性疾患および感染を診断するための方法
WO2013106913A1 (fr) Biomarqueurs pour le pronostic et le traitement du cancer du sein
US20110082349A1 (en) Means and methods for determining the arteriosclerotic stenosis using inflammatory biomarkers
EP3217175A1 (fr) Procédé de détection de l&#39;artériosclérose et de cancer à l&#39;aide de gène de désoxyhypusine synthase comme indicateur
US20100273268A1 (en) Determining atherosclerotic load using placental growth factor
CN110678757A (zh) 诊断或监测肾功能或诊断肾功能障碍的方法
WO2009153175A1 (fr) Procédés et moyens de diagnostic du cancer du pancréas
WO2017057308A1 (fr) Anticorps pour reconnaître et fixer spécifiquement la protéine reic/dkk-3 à structure active, et suivi de traitement du cancer dans lequel ledit anticorps anti-reic/dkk-3 est utilisé
US8440463B2 (en) Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1
US20100086946A1 (en) Plgf, flt1 and endoglin for diagnosing angiogenic status in coronary artery disease
EP2037278A1 (fr) Marqueurs vasculaires pour le remodelage d&#39;une lésion cardiaque
CN106459166B (zh) 检测肉瘤转移的方法和生物标记物
KR20240068432A (ko) 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트
EP2812701A1 (fr) Ensemble de biomarqueurs destinés à identifier une forme grave de cancer
EP2508890A1 (fr) Diagnostic de l&#39;insuffisance cardiaque à base de CAIX

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09765755

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09765755

Country of ref document: EP

Kind code of ref document: A1